CORRECTION: HC Wainwright & Co. Reiterates Buy on Freeline Therapeutics, Maintains $15 Price Target - Analyst Firm Updated
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.
August 04, 2023 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics (NASDAQ:FRLN) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The firm has also maintained a $15 price target.
The reiteration of a 'Buy' rating and maintenance of a $15 price target by HC Wainwright & Co. indicates a positive outlook for Freeline Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100